GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Cash Flow for the year ending December 31, 2023: USD 38.97 M

GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Cash Flow is USD 38.97 M for the year ending December 31, 2023, a -8.30% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Cash Flow for the year ending December 31, 2022 was USD 42.50 M, a 74.18% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Cash Flow for the year ending December 31, 2021 was USD 24.40 M, a 151.82% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Cash Flow for the year ending December 31, 2020 was USD 9.69 M, a -41.95% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Cash Flow for the year ending December 31, 2019 was USD 16.69 M, a 52.36% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years